Print this page
-
A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC.
Protocol: 032111Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
ARAR2221: A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Protocol: 112405Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial.
Protocol: 132004Principal Investigator:
- Sharon Manne PhD (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
- 1
- 2